Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Neuroscience ; 166(2): 508-21, 2010 Mar 17.
Article in English | MEDLINE | ID: mdl-20045450

ABSTRACT

Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that can be released or activated in a neuronal activity dependent manner. Although pathologically elevated levels of MMPs may be synaptotoxic, physiologically appropriate levels of MMPs may instead enhance synaptic transmission. MMP inhibitors can block long term potentiation (LTP), and at least one family member can affect an increase in the volume of dendritic spines. While the mechanism by which MMPs affect these changes is not completely understood, one possibility is that the cleavage of specific synaptic cell adhesion molecules plays a role. In the present study, we have examined the ability of neuronal activity to stimulate rapid MMP dependent shedding of the intercellular adhesion molecule-5 (ICAM-5), a synaptic adhesion molecule that is thought to inhibit the maturation and enlargement of dendritic spines. Since such cleavage would likely occur within minutes if it were relevant to a process such as LTP, we focused on post stimulus time points of 30 min or less. We show that NMDA can stimulate rapid shedding of ICAM-5 from cortical neurons in dissociated cell cultures and that such shedding is diminished by pretreatment of cultures with inhibitors that target MMP-3 and -9, proteases thought to influence synaptic plasticity. Additional studies suggest that MMP mediated cleavage of ICAM-5 occurs at amino acid 780, so that the major portion of the ectodomain is released. Since reductions in ICAM-5 have been linked to changes in dendritic spine morphology that are associated with LTP, we also examined the possibility that MMP dependent ICAM-5 shedding occurs following high frequency tetanic stimulation of murine hippocampal slices. Results show that the shedding of ICAM-5 occurs in association with LTP, and that both LTP and the associated ICAM-5 shedding are reduced when slices are pretreated with an MMP inhibitor. Together, these findings suggest that neuronal activity is linked to the shedding of a molecule that may inhibit dendritic spine enlargement and that MMPs can affect this change. While further studies will be necessary to determine the extent to which cleavage of ICAM-5 in particular contributes to MMP dependent LTP, our data support an emerging body of literature suggesting that MMPs are critical mediators of synaptic plasticity.


Subject(s)
Cell Adhesion Molecules/metabolism , Hippocampus/metabolism , Long-Term Potentiation/physiology , Matrix Metalloproteinases/metabolism , Nerve Tissue Proteins/metabolism , Neurons/metabolism , Analysis of Variance , Animals , Blotting, Western , Cells, Cultured , Dendritic Spines/metabolism , Electric Stimulation , Electrophysiology , Hippocampus/cytology , Hippocampus/drug effects , Immunohistochemistry , N-Methylaspartate/pharmacology , Neuronal Plasticity/drug effects , Neuronal Plasticity/physiology , Neurons/cytology , Neurons/drug effects , Rats
2.
Neuroscience ; 149(1): 87-98, 2007 Oct 12.
Article in English | MEDLINE | ID: mdl-17826919

ABSTRACT

Matrix metalloproteinase-7 (MMP-7) belongs to a family of zinc dependent endopeptidases that are expressed in a variety of tissues including the brain. MMPs are known to be potent mediators of pericellular proteolysis and likely mediators of dynamic remodelling of neuronal connections. While an association between proteases and the neuronal synapse is emerging, a full understanding of this relationship is lacking. Here, we show that MMP-7 alters the structure and function of presynaptic terminals without affecting neuronal survival. Bath application of recombinant MMP-7 to cultured rat neurons induced long-lasting inhibition of vesicular recycling as measured by synaptotagmin 1 antibody uptake assays and FM4-64 optical imaging. MMP-7 application resulted in reduced abundance of vesicular and active zone proteins locally within synaptic terminals although their general levels remained unaltered. Finally, chronic application of the protease resulted in synaptic atrophy, including smaller terminals and fewer synaptic vesicles, as determined by electron microscopy. Together these results suggest that MMP-7 is a potent modulator of synaptic vesicle recycling and synaptic ultrastructure and that elevated levels of the enzyme, as may occur with brain inflammation, may adversely influence neurotransmission.


Subject(s)
Matrix Metalloproteinase 7/pharmacology , Neurons/drug effects , Synapses/drug effects , Synapses/pathology , Synaptic Vesicles/drug effects , Animals , Atrophy , Cells, Cultured , Embryo, Mammalian , Gene Expression Regulation/drug effects , Hippocampus/cytology , Humans , Matrix Metalloproteinase 1/pharmacology , Microscopy, Immunoelectron/methods , Protein Transport/drug effects , Pyridinium Compounds , Quaternary Ammonium Compounds , Rats , Rats, Sprague-Dawley , Synaptic Vesicles/metabolism , Synaptic Vesicles/ultrastructure , Synaptophysin/metabolism , Synaptotagmin I/metabolism , Vesicle-Associated Membrane Protein 2/metabolism
3.
J Neuroimmunol ; 187(1-2): 9-19, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17555826

ABSTRACT

The matrix metalloproteinases (MMPs) are expressed in response to pro-inflammatory stimuli and other triggers. The MMPs cleave numerous substrates including extracellular matrix components, cytokines and growth factors. In the CNS, while most studied in the context of disease, the many physiological functions of the MMPs are now becoming appreciated. This review provides an overview of the growing body of evidence for physiological roles of MMPs both in CNS development and in CNS plasticity in normal brain functioning, including learning and memory, as well as in CNS repair and reorganization as part of the neuroimmune response to injury.


Subject(s)
Central Nervous System , Matrix Metalloproteinases/physiology , Neuronal Plasticity/physiology , Animals , Central Nervous System/cytology , Central Nervous System/growth & development , Central Nervous System/metabolism , Gene Expression Regulation, Developmental/physiology , Gene Expression Regulation, Enzymologic/physiology , Humans
4.
J Neurovirol ; 13(1): 2-10, 2007.
Article in English | MEDLINE | ID: mdl-17454443

ABSTRACT

Although neurological symptoms associated with cerebral malaria (CM) are largely reversible, recent studies suggest that lasting neurological sequelae can occur. This may be especially true for children, in whom persistent deficits include problems with memory and attention. Because the malaria parasite is not thought to enter the brain parenchyma, lasting deficits are likely related to factors including the host response to disease. Studies with a rodent model, and with human postmortem tissue, suggest that glial activation occurs with CM. In this review, the authors will highlight studies focused on such activation in CM. Likely causes will be discussed, which include ischemia and activation of blood brain barrier endothelial cells. The potential consequences of glial activation will also be discussed, highlighting the possibility that glial-derived proteinases contribute to structural damage of the central nervous system (CNS). Of note, for the purposes of this focused review, glial activation will refer to the activation of astrocytes and microglial cells; discussion of oligodendroglial cells will not be included. In addition, although events thought to be critical to the pathogenesis of CM and glial activation will be covered, a comprehensive review of cerebral malaria will not be presented. Excellent reviews are already available, including Coltel et al (2004; Curr Neurovasc Res 1: 91-110), Medana and Turner (2006; Int J Parasitol 36: 555-568), and Hunt et al (2006; Int J Parasitol 36: 569-582).


Subject(s)
Central Nervous System Infections/cerebrospinal fluid , Central Nervous System/immunology , Malaria, Cerebral/enzymology , Malaria, Cerebral/pathology , Microglia/physiology , Animals , Central Nervous System/pathology , Central Nervous System Infections/physiopathology , Enzyme Activation , Humans , Malaria, Cerebral/immunology , Matrix Metalloproteinase 9/blood , Matrix Metalloproteinase 9/cerebrospinal fluid , Microglia/cytology
5.
Eur J Pharmacol ; 378(3): 249-58, 1999 Aug 13.
Article in English | MEDLINE | ID: mdl-10493100

ABSTRACT

Since the melanocortin MC3 and melanocortin MC4 receptors are the main melanocortin receptor subtypes expressed in rat brain, we characterized the activity and affinity of nine melanocortin receptor ligands using these receptors in vitro, as well as their activity in a well-defined melanocortin-induced behavior in the rat: grooming behavior. We report here that [D-Tyr4]melanotan-II and RMI-2001 (Ac-cyclo-[Cys4, Gly5, D-Phe7, Cys10]alpha-MSH-NH2) have significantly higher affinity and potency on the rat melanocortin MC4 receptor as compared to the rat melanocortin MC3 receptor. Nle-gamma-MSH (melanocyte-stimulating hormone) was the only ligand with higher affinity and potency on the rat melanocortin MC3 receptor. The potency order of melanocortin MC4 receptor agonists, but not that of melanocortin MC3 receptor agonists, fitted with the potency of these ligands to stimulate grooming behavior, when administered intracerebroventricularly. SHU9119 (Ac-cyclo-[Nle4, Asp5, D-Nal(2)7, Lys10]alpha-MSH-(4-10)-NH2) and RMI-2005 (Ac-cyclo-[Cys4, Gly5, D-Na](2)7, Nal(2)9, Cys10]alpha-MSH-(4-10)-NH2) were able to inhibit alpha-MSH-induced melanocortin receptor activity in vitro, as well as alpha-MSH-induced grooming behavior. Melanotan-II, [Nle4-D-Phe7]alpha-MSH and RMI-2001 were also effective in inducing grooming behavior when administered intravenously. In the absence of purely selective melanocortin MC(3/4) receptor ligands, we demonstrated that careful comparison of ligand potencies in vitro with ligand potencies in vivo, could identify which melanocortin receptor subtype mediated alpha-MSH-induced grooming behavior. Furthermore, blockade of novelty-induced grooming behavior by SHU9119 demonstrated that this physiological stress response is mediated via activation of the melanocortin system.


Subject(s)
Grooming/drug effects , Ligands , Receptors, Corticotropin/metabolism , Amino Acid Sequence , Animals , Binding, Competitive , Catheterization , Cell Line , Dose-Response Relationship, Drug , Drug Interactions , Humans , Injections, Intravenous , Injections, Intraventricular , Melanocyte-Stimulating Hormones/pharmacology , Molecular Sequence Data , Peptide Fragments/pharmacology , Radioligand Assay , Rats , Rats, Wistar , Receptor, Melanocortin, Type 3 , Receptor, Melanocortin, Type 4 , Receptors, Corticotropin/antagonists & inhibitors , Receptors, Corticotropin/drug effects , Receptors, Corticotropin/genetics , Receptors, Melanocortin , Recombinant Fusion Proteins/drug effects , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Sequence Homology, Amino Acid , Time Factors , alpha-Galactosidase/drug effects , alpha-Galactosidase/genetics , alpha-Galactosidase/metabolism , alpha-MSH/metabolism , alpha-MSH/pharmacology
6.
J Biol Chem ; 274(40): 28106-12, 1999 Oct 01.
Article in English | MEDLINE | ID: mdl-10497161

ABSTRACT

Understanding of biological function of AP-1 transcription factor in central nervous system may greatly benefit from identifying its target genes. In this study, we present several lines of evidence implying AP-1 in regulating expression of tissue inhibitor of metalloproteinases-1 (timp-1) gene in rodent hippocampus in response to increased neuronal excitation. Such a notion is supported by the findings that timp-1 mRNA accumulation occurs in the rat hippocampus after either kainate- or pentylenetetrazole-evoked seizures with a delayed, in comparison with AP-1 components, time course, as well as with spatial overlap with c-Fos protein (major inducible AP-1 component) expression. Furthermore, AP-1 sequence derived from timp-1 promoter is specifically bound by hippocampal AP-1 proteins after treating the rats with either pro-convulsive agent. Finally, timp-1 promoter responds to excitatory activation both in vivo, in transgenic mice harboring the timp-LacZ gene construct, and in vitro in neurons of the hippocampal dentate gyrus cultures. These findings suggest that the AP-1 transcription factor may exert its role in the brain through affecting extracellular matrix remodeling.


Subject(s)
Dentate Gyrus/metabolism , Gene Expression Regulation/physiology , Neurons/physiology , Tissue Inhibitor of Metalloproteinase-1/genetics , Transcription Factor AP-1/physiology , Animals , Cells, Cultured , Dentate Gyrus/cytology , Lac Operon , Male , Mice , Mice, Transgenic , Promoter Regions, Genetic , Protein Binding , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Wistar , Regulatory Sequences, Nucleic Acid , Transcription Factor AP-1/metabolism
8.
Antisense Nucleic Acid Drug Dev ; 9(1): 105-16, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10192296

ABSTRACT

During the last few years, antisense oligodeoxyribonucleotides (asODN) have become a commonly used tool for blocking of gene expression in the mammalian central nervous system. Successful gene inhibition has been reported for such diverse targets as those encoding neurotransmitter receptors, neuropeptides, trophic factors, transcription factors, cytokines, transporters, ion channels, and others. This review presents a discussion of recent studies on ODN in the brain, with a focus on specific approaches taken by the researchers in this field and especially on peculiar features of this organ as a milieu for asODN action. It is concluded that from the presented literature survey no coherent view on how to rationally design ODN for brain studies has emerged.


Subject(s)
Brain/metabolism , Oligodeoxyribonucleotides, Antisense/pharmacology , Oligodeoxyribonucleotides, Antisense/pharmacokinetics , Animals , Brain/cytology , Brain/drug effects , Drug Carriers , Gene Expression Regulation/drug effects , Oligodeoxyribonucleotides, Antisense/adverse effects , Oligodeoxyribonucleotides, Antisense/genetics
9.
Neuroscience ; 84(2): 467-77, 1998 May.
Article in English | MEDLINE | ID: mdl-9539217

ABSTRACT

Dystrophin and dystroglycan messenger RNAs are expressed in specific brain areas, including regions of the cortex and the hippocampus, and in such neurons dystrophin has been localized to postsynaptic densities. In the present study we examined by in situ hybridization the effect of neuronal activation and neurotoxicity induced by kainate and pentylenetetrazole administered in vivo on dystrophin and dystroglycan expression in the rat brain. Kainate injection resulted in a transient but dramatic decrease in dystrophin transcript levels in the dentate gyrus granule cells, neurons not affected by kainate neurotoxicity, 6 h after injection. There was also a strong, concomitant increase in dystrophin messenger RNA levels in the CA3 subfield. At 24-72 h after kainate injection, the dystrophin transcript in the dentate granule cells returned to control levels, while it decreased gradually in the CA subfields, coinciding with the neurodegeneration observed in these areas. Comparable results were obtained with pan-dystrophin probes and probes specific to the short, G-dystrophin (Dp71) isoform that predominates in the dentate gyrus. This indicates that any dystrophin transcript that might be expressed in these areas responds to kainate in the same manner. In contrast, kainate insult had no significant effect on the dystroglycan messenger RNA levels in these hippocampal areas at 6 h post-injection. At later times. however, there was a gradual decrease in the dystroglycan messenger RNA in those areas which respond to the kainate insult with extensive neuronal death. For comparison, seizures which are not associated with progressive neurodegeneration were induced by pentylenetetrazole: in this situation the dystrophin and dystroglycan messenger RNA levels remained unchanged in all areas of the hippocampal formation. Since activation of glutamate receptors is thought to be involved in some forms of synaptic plasticity in the adult hippocampus, our data indicate that the dystrophin gene behaves as a candidate plasticity-related gene responding to glutamate.


Subject(s)
Dystrophin/biosynthesis , Gene Expression Regulation/drug effects , Hippocampus/metabolism , Kainic Acid/pharmacology , Neurons/metabolism , Transcription, Genetic/drug effects , Animals , Base Sequence , Cytoskeletal Proteins/biosynthesis , DNA Probes , Dystroglycans , Hippocampus/drug effects , In Situ Hybridization , Kinetics , Male , Membrane Glycoproteins/biosynthesis , Molecular Sequence Data , Neurons/drug effects , RNA, Messenger/biosynthesis , Rats , Rats, Wistar
10.
Neuroscience ; 86(2): 499-510, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9881864

ABSTRACT

In order to explore the role of CREM (cyclic-AMP responsive element modulator) gene expression in the function of the central nervous system, the gene transcripts were investigated in the rat brain in several conditions linked to increased neuronal activity. Up-regulation of CREM messenger RNA levels in the hippocampus was found to follow intraperitoneal administration of kainate (10 mg/kg). This increase was observed in both the dentate gyrus and hippocampus proper (CA subfields) and reached its maximum at 6 h after the treatment. Intrahippocampal injection of N-methyl-D-aspartate (200 nmol) resulted in elevated CREM messenger RNA expression as well. A similar increase of the messenger RNA abundance was also observed in the retrosplenial cortex after treating the female rats with a high dose (5 mg/kg) of dizocilpine maleate, an N-methyl-D-aspartate receptor antagonist. All these conditions are linked to neuronal excitation and neurodegeneration. However, an increase in CREM messenger RNA accumulation was also observed in the visual cortex after exposure of dark-adapted animals to the light, a procedure linked to neuronal plasticity. In the latter condition, it was found that CREM messenger RNA reached its highest levels at 6 h, i.e. later than the maximal increase of expression of immediate early genes such as c-fos, jun B and zif268, observed 45 min following the onset of visual stimulation. The ICER (inducible cyclic-AMP early repressor) form of CREM messenger RNA was identified to be induced by the light exposure. Finally, it was also found that cycloheximide, an inhibitor of protein synthesis, overinduces CREM/ICER gene expression. Together, these data suggest that CREM/ICER may be responsive to neuronal activation. Furthermore, given that CREM products have been shown previously to down-regulate expression of immediate early genes in vitro, they suggest that ICER may function as a molecular switch involved in down-regulation of immediate early gene expression in the rat brain.


Subject(s)
Brain/physiology , DNA-Binding Proteins/genetics , Gene Expression Regulation/drug effects , Immediate-Early Proteins , Kainic Acid/pharmacology , N-Methylaspartate/pharmacology , Neuronal Plasticity/physiology , Transcription, Genetic , Animals , Brain/drug effects , Cyclic AMP/physiology , Cyclic AMP Response Element Modulator , Darkness , Dizocilpine Maleate/pharmacology , Early Growth Response Protein 1 , Female , Functional Laterality , Genes, fos , Genes, jun , Hippocampus/drug effects , Hippocampus/physiology , In Situ Hybridization , Light , Male , Photic Stimulation , RNA, Messenger/genetics , Rats , Rats, Wistar , Repressor Proteins/genetics , Transcription Factors/genetics , Transcription, Genetic/drug effects
11.
Neurochem Int ; 31(3): 413-23, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9246683

ABSTRACT

A thorough evaluation of the pharmacokinetical properties of oligodeoxyribonucleotides (ODN) is a first step towards their rational application as gene expression blockers in the central nervous system (CNS). In this paper we present our own data, as well as those of other authors, on tissue distribution, stability, retention and cellular uptake of phosphodiester, phosphorothioate, and end-capped analogues of ODN introduced into the CNS. ODN are easily distributed within nervous tissue, and their tissue penetration depends on anatomical conditions. Retention of radioactivity delivered with ODN within nervous tissue is higher for phosphodiesters than for phosphorothioates. On the other hand, the tissue stability of phosphorothioates is substantially greater than the tissue stability of phosphodiesters as well as that of end-capped ODN. If the elimination process of ODN is also due to their degradation, it is apparently accomplished by endonucleases, because the recovery of end-capped ODN (resistant to exonucleases) was similar to unprotected phosphodiesters. The uptake of ODN by nerve cells is rather poor, although we have shown that phosphorothioates at least can be internalized by nerve cells in vivo. ODN are metabolized by nerve cells, which results in the formation of unidentified molecules of higher molecular weight than ODN themselves.


Subject(s)
Central Nervous System/metabolism , Oligonucleotides, Antisense/pharmacokinetics , Thionucleotides/pharmacokinetics , Animals , Central Nervous System/cytology , Hippocampus/metabolism , Neurons/metabolism , Tissue Distribution
12.
Acta Biochim Pol ; 44(4): 781-9, 1997.
Article in English | MEDLINE | ID: mdl-9584860

ABSTRACT

Kainate is a glutamate analog that produces neuronal excitation resulting in seizures within hours following its intraperitoneal injection into adult rats. Then, at 2-3 days after the treatment, neurodegeneration of apoptotic character can be observed in limbic system. As a consequence, plastic reorganization and glial reactivation phenomena occur. These physiological and pathological responses are reflected by specific changes in gene expression, that can be dissected according to their spatio-temporal patterns. The early phase of gene expression observed in all hippocampal subfields appears to reflect a sudden burst of spiking activity. Changes in mRNA levels restricted to dentate gyrus are suggestive of a link to neuronal plasticity. The late gene expression response implies its correlation either to neuronal cell death or glial reactivation, depending on cellular localization of gene products. Thus analysis of the temporal and spatial gene expression pattern in the hippocampus after kainate treatment may provide clues revealing specific phenomena to which gene expression could be attributed.


Subject(s)
Brain/drug effects , Brain/metabolism , Gene Expression/drug effects , Kainic Acid/pharmacology , Animals , Dystrophin/genetics , Excitatory Amino Acids/pharmacology , Models, Neurological , Nerve Degeneration/chemically induced , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Receptors, Glutamate/drug effects , Receptors, Glutamate/metabolism , Seizures/chemically induced , Transcription Factors/genetics , Transcription Factors/metabolism
13.
J Neurosci Methods ; 60(1-2): 181-7, 1995 Aug.
Article in English | MEDLINE | ID: mdl-8544478

ABSTRACT

As a prerequisite for blocking specific gene expression in the brain, the pharmacokinetics of two radiolabelled analogs of antisense oligodeoxyribonucleotides (unmodified O-ODN and nuclease resistant phosphorothioate S-ODN) were examined by infusion into the baso-lateral nucleus of amygdala. Both ODN analogs were found to penetrate at restricted distances into the brain tissue. Rapidly after injection, O-ODN was almost completely degraded, while S-ODN remained intact up to 24 h following administration as examined by gel electrophoresis of nucleic acids recovered from the injection site. The tissue clearance of the radioactivity delivered in a form of O-ODN and S-ODN was also different, the former characterized by much better tissue retention. Microscopic studies suggested that S-ODN can apparently penetrate across the cell membrane and accumulate both in the cytoplasm in the cell nucleus. In situ hybridisation histochemistry experiments (antisense probe to injected ODN) revealed that injected S-ODN was present in a form available for annealing with the complementary strand. Our results provide a basic description of the distribution, retention, and stability of antisense oligonucleotides injected into brain tissue.


Subject(s)
Brain/metabolism , Oligodeoxyribonucleotides/pharmacokinetics , Oligonucleotides, Antisense/pharmacokinetics , Amygdala/metabolism , Animals , DNA Nucleotidylexotransferase/metabolism , In Situ Hybridization , Injections , Male , Oligodeoxyribonucleotides/administration & dosage , Oligonucleotides, Antisense/administration & dosage , Proto-Oncogene Proteins c-fos/biosynthesis , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...